Adhithi Rajagopalan
Overview
Explore the profile of Adhithi Rajagopalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
James S, Chen S, Ng B, Fischman J, Jahn L, Boardman A, et al.
Nat Biomed Eng
. 2024 Dec;
8(12):1592-1614.
PMID: 39715901
Resistance to chimaeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms, most notably antigen loss and tumour-induced immune suppression. It has been suggested that T cells expressing multiple...
2.
Elias H, Mitra S, da Silva M, Rajagopalan A, Gipson B, Lee N, et al.
bioRxiv
. 2024 Jun;
PMID: 38895335
Hematopoietic stem cells (HSCs) with multilineage potential are critical for effective T cell reconstitution and restoration of the adaptive immune system after allogeneic Hematopoietic Cell Transplantation (allo-HCT). The Kit subset...
3.
Ng B, Rajagopalan A, Kousa A, Fischman J, Chen S, Massa A, et al.
Blood
. 2024 Apr;
144(2):171-186.
PMID: 38579288
Multiple myeloma is a plasma cell malignancy that is currently incurable with conventional therapies. Following the success of CD19-targeted chimeric antigen receptor (CAR) T cells in leukemia and lymphoma, CAR...
4.
Rajagopalan A, Feng Y, Gayatri M, Ranheim E, Klungness T, Matson D, et al.
J Clin Invest
. 2023 Oct;
133(24).
PMID: 37847561
We previously demonstrated that a subset of acute myeloid leukemia (AML) patients with concurrent RAS pathway and TP53 mutations have an extremely poor prognosis and that most of these TP53...
5.
Peat T, Gaikwad S, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, et al.
Cancer Lett
. 2023 Jun;
568:216284.
PMID: 37356470
Drug resistance and disease progression are common in multiple myeloma (MM) patients, underscoring the need for new therapeutic combinations. A high-throughput drug screen in 47 MM cell lines and in...
6.
Flietner E, Yu M, Poudel G, Veltri A, Zhou Y, Rajagopalan A, et al.
Oncogene
. 2023 Apr;
42(21):1751-1762.
PMID: 37031341
Multiple myeloma (MM) is a cancer of malignant plasma cells in the bone marrow and extramedullary sites. We previously characterized a VQ model for human high-risk MM. The various VQ...
7.
Flietner E, Wen Z, Rajagopalan A, Jung O, Watkins L, Wiesner J, et al.
Sci Rep
. 2022 Jun;
12(1):10616.
PMID: 35739276
Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent in advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed a...
8.
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, et al.
Blood
. 2021 Oct;
139(7):1066-1079.
PMID: 34699595
Mutations in chromatin regulator ASXL1 are frequently identified in myeloid malignancies, in particular ∼40% of patients with chronic myelomonocytic leukemia (CMML). ASXL1 mutations are associated with poor prognosis in CMML...
9.
Wen Z, Rajagopalan A, Flietner E, Yun G, Chesi M, Furumo Q, et al.
Blood
. 2020 Jul;
137(1):61-74.
PMID: 32640012
NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and correlate with poor patient outcomes. Thus, we generated a novel MM model by conditionally activating expression of endogenous NrasQ61R...
10.
Kong G, You X, Wen Z, Chang Y, Qian S, Ranheim E, et al.
Leukemia
. 2018 Sep;
33(3):671-685.
PMID: 30206308
The Notch signaling pathway contributes to the pathogenesis of a wide spectrum of human cancers, including hematopoietic malignancies. Its functions are highly dependent on the specific cellular context. Gain-of-function NOTCH1...